Twist Bioscience Corporation

DB:0ME Stock Report

Market Cap: €2.7b

Twist Bioscience Past Earnings Performance

Past criteria checks 0/6

Twist Bioscience's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 31.1% per year.

Key information

-12.3%

Earnings growth rate

1.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate31.1%
Return on equity-44.2%
Net Margin-66.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Twist Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:0ME Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24313-20921891
30 Jun 24295-22021393
31 Mar 24277-19220296
31 Dec 23262-20620099
30 Sep 23245-205190107
30 Jun 23235-209197113
31 Mar 23228-213204125
31 Dec 22216-214204129
30 Sep 22204-218213120
30 Jun 22184-208197110
31 Mar 22163-18817893
31 Dec 21146-16515878
30 Sep 21132-15213669
30 Jun 21127-13512561
31 Mar 21113-12311352
31 Dec 20101-11710647
30 Sep 2090-14010343
30 Jun 2073-14710142
31 Mar 2066-1479940
31 Dec 1960-1419139
30 Sep 1954-1088036
30 Jun 1947-966931
31 Mar 1940-865928
31 Dec 1833-774923
30 Sep 1825-714320
30 Jun 1820-683919
30 Sep 1711-592619
30 Sep 162-441818

Quality Earnings: 0ME is currently unprofitable.

Growing Profit Margin: 0ME is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0ME is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare 0ME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0ME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0ME has a negative Return on Equity (-44.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:34
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Twist Bioscience Corporation is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Gaurav GoparajuBerenberg